Exagen
XGN
30 hedge funds and large institutions have $14.1M invested in Exagen in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
3% more funds holding
Funds holding: 29 → 30 (+1)
0.79% more ownership
Funds ownership: 40.72% → 41.51% (+0.79%)
16% less capital invested
Capital invested by funds: $16.7M → $14.1M (-$2.59M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$842K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$424K |
| 3 |
CAC
Cowen and Company
New York
|
+$97.3K |
| 4 |
Renaissance Technologies
New York
|
+$78.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$923K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$118K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$31.8K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$16.7K |
| 5 |
BlackRock
New York
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $9.85K | +$8.56K | +4,952 | New |
|
27
Wells Fargo
San Francisco,
California
| $4.89K | +$7 | +4 | +0.2% |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$5.47K | -3,165 | -85% |
|
29
Qube Research & Technologies (QRT)
London,
United Kingdom
| $406 | – | – | – |
|
30
JP Morgan Chase
New York
| $50 | -$3.9K | -2,252 | -99% |
|
31
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.57K | -650 | Closed |
|
|
SOW
32
State of Wyoming
Cheyenne,
Wyoming
| – | -$1.59K | -649 | Closed |
|
XGN Hedge Fund Activity: Q4 2023 in Review
30 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q4 2023, worth a combined $14.1M — down 16% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XGN positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 11 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $842K. The largest seller was Stonepine Capital Management, cutting an estimated $923K.
- 30 institutional investors held Exagen (XGN) as of Q4 2023, up from 29 in Q3 2023.
- Funds reported $14.1M of Exagen stock for Q4 2023, down 16% quarter-over-quarter.
- 3 funds opened new Exagen positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Exagen buyer in Q4 2023 was Morgan Stanley, an estimated $842K added.
- The largest Exagen seller in Q4 2023 was Stonepine Capital Management, an estimated $923K sold.
Based on aggregated 13F filings for Q4 2023.